Prevalence and Patterns of Use of Psychoactive Medicines in Individuals with Autism in the Autism Society of North Carolina
- 1 December 2002
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Child and Adolescent Psychopharmacology
- Vol. 12 (4) , 311-321
- https://doi.org/10.1089/104454602762599853
Abstract
The aim of this study was to assess the prevalence and patterns of psychoactive and over-the-counter medicines in a large cohort of individuals with autism. We conducted a mail survey of 3,228 families that are members of the Autism Society of North Carolina. This is one of the largest chapters of the Autism Society of America. The survey form addressed current medicines used, side effects, demographic characteristics, and medical conditions. Some 1,538 member families within the society (48%) responded to the survey. In all, 703 (45.7%) individuals with autism were taking psychotropic drugs, 191 (12.4%) antiepileptic drugs (AEDs), and 86 (5.7%) supplements for autism. The total number taking psychotropic, antiepileptic, or vitamin treatments was 816 (53.1%). Antidepressants (taken by 21.7% of the sample), antipsychotics (16.8%), and stimulants (13.9%) were the most commonly prescribed agents. Univariate and multivariate analyses were conducted to examine factors associated with treatment. Greater age, more severe autism and mental retardation, and more restricted housing were often associated with greater use of psychoactive agents. These findings suggest that individuals with autism are a frequently medicated group, although the empirical research support for most agents being used is still very limited.Keywords
This publication has 16 references indexed in Scilit:
- Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2001
- Does Fast Dissociation From the Dopamine D2Receptor Explain the Action of Atypical Antipsychotics?: A New HypothesisAmerican Journal of Psychiatry, 2001
- Review of serotonergic agents and perseverative behavior in patients with developmental disabilitiesMental Retardation and Developmental Disabilities Research Reviews, 1999
- Atypical antipsychotics in persons with developmental disabilitiesMental Retardation and Developmental Disabilities Research Reviews, 1999
- High-Dose Pyridoxine and Magnesium Administration in Children with Autistic Disorder: An Absence of Salutary Effects in a Double-Blind, Placebo-Controlled StudyJournal of Autism and Developmental Disorders, 1997
- Long-Term Follow-Up of Children with Mental Retardation/Borderline Intellectual Functioning and ADHDJournal of Abnormal Child Psychology, 1997
- Psychotropic and Anticonvulsant Drugs in Subjects with Autism: Prevalence and Patterns of UseJournal of the American Academy of Child & Adolescent Psychiatry, 1995
- A Double-blind Comparison of Clomipramine, Desipramine, and Placebo in the Treatment of Autistic DisorderArchives of General Psychiatry, 1993
- Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental RetardationJournal of the American Academy of Child & Adolescent Psychiatry, 1992
- Clinical Effects of Methylphenidate and Thioridazine in Intellectually Subaverage ChildrenJournal of the American Academy of Child & Adolescent Psychiatry, 1991